Cholinergic and perfusion brain networks in Parkinson disease dementia
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 28, 2015
- Accepted in final form March 30, 2016
- First Published June 15, 2016.
Article Versions
- Previous version (June 15, 2016 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Sean J. Colloby, PhD,
- Ian G. McKeith, MD,
- David J. Burn, MD,
- David J. Wyper, PhD,
- John T. O'Brien, DM* and
- John-Paul Taylor, PhD*
- Sean J. Colloby, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ian G. McKeith, MD,
(1) GE Healthcare (2) Nutricia (3) Axovant Sciences
NONE
(1) GE Healthcare (2) Nutricia
(1) Alzheimer's Research and Therapy
NONE
NONE
NONE
NONE
(1) GE Healthcare
NONE
NONE
(1) GE Healthcare
(1) NIHR BRC 2012-17 (2) NIHR Dendron 2010-15
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David J. Burn, MD,
Profile Pharma - Chairing one panel on safinamide in UK (2016)
NONE
Acadia Pharmaceuticals: speaker honorarium at Movement Disorders Meeting in San Diego 2015
NONE
NONE
Henry Stewart publishers for online movement disorders resource Oxford University Press for Editing
NONE
BIAL - payment to University (not personal)in 2015
NONE
NONE
NONE
NONE
A Biomedical Research Unit in Lewy Body Dementia. NIHR: 1st April 2012 - 31st March 2017; (Burn DJ, McKeith IG, O?Brien JT, Kirkwood TBL, Chinnery PF, Ford GA).
NONE
Parkinson's UK: Visual symptoms in Parkinson?s disease and Parkinson?s disease dementia: Association with ocular and retinal pathology, visuo-perceptual deficits and impact on daily living and quality of life. Parkinson?s UK: November 2007- October 2010; (Archibald N, Mosimann UP, Clarke MP, Burn DJ). Predicting Dementia in Parkinson?s disease: A genotypic and phenotypic study (ICICLE-PD). Parkinson?s UK REF J0802, UK: October 2007 ? September 2012; (Burn DJ, Barker RA, Brooks DJ, O?Brien JT, McKeith IG, Chinnery PF, Owen AM, Brayne CEG, Robbins T, Sawcer S, Coleman S). The Parkinson?s Repository of Biomarkers and Networked Datasets (PROBAND) programme: A UK national clinical consortium linking novel biomarker research to clinical expression, and progression rates, in Parkinson?s disease. Parkinson?s UK: 2011-2015; (Grosset D, Burn DJ, Barker RA, Ben-Shlomo Y, Bajaj N, Hardy J, Wood NW, Morris HR). Apomorphine: A modifier of amyloid deposition in Parkinson?s disease? Parkinson?s UK REF K-1101: October 2011 - April 2012;(Burn DJ, Revesz T, Lees AJ). Michael J Fox Foundation Clinical trial to compare cognitive scales. Michael J Fox Foundation: 1st October 2011 - 30th September 2016; (Burn DJ, Weintraub D). Predicting cognitive profiles in Parkinson?s disease: A multimodal approach. Michael J Fox Foundation: 1st November 2011 - 31st October 2013; (Burn DJ, Rochester L, O?Brien JT, Coleman SY, Baker MR).
NONE
NONE
NONE
NONE
NONE
NONE
- David J. Wyper, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John T. O'Brien, DM* and
(1) TAURx (2) Cytox
NONE
(1) Pfizer, speaker honoraria (2) GE Healthcare, speaker honoraria (3) Eisai, speaker honoraria (4) Shire, speaker honoraria (5) Lundbeck, speaker honoraria (6) Lilly, speaker honoraria (7) Novartis, speaker honoraria
(1) Psychological Medicine, Editorial Board (2) International Psychogeriatrics, Deputy Editor
NONE
NONE
NONE
(1) GE Healthcare (2) Bayer Healthcare (3) Lilly
NONE
NONE
NONE
(1) Lilly
(1) Parkinson?s Disease Society 01.10.2007-30.09.2010; (2) Sir Jules Thorn Charitable Trust, 01.02.2006- 31.01.2011; (3) DoH/Wellcome Trust, 01.06.2006-31.05.2011; (4) Medical Research Council, 01.11.2007-31.12.2013; (5) Parkinson's Disease Society, 01.02.2009-31.01.2014; (6) Member of the NIHR College of Senior Investigators, 01.04.2009-31.03.2014; (7) NIHR, 01.03.2010-28.02.2013; (8) Wellcome Trust Intermediate Fellowship, 01.05.2010- 30.04.2013; (9) NIHR-RfPB, 01.08.2010-31.07.2012. (10) The Food Standards Agency, 01.12.2010-31.07.2013. (11) BUPA/Alzheimer's Society, 01.12.2010-30.11.2012. (12) British Heart Foundation/The Stroke Association, 01.01.2011-31.12.2015. (13) HTA, 01.03.2011-30.04.2014. (14) Alzheimer's Research Trust, 01.03.2011-31.08.2012.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John-Paul Taylor, PhD*
(1)Scientific Advisor to Lewy body Society - non-profit entity (2)Cognition Advisory Group (Michael J Fox Foundation) - non-profit entity
NONE
(1) GE Healthcare, speaker honoraria (2) Flynn Pharmaceuticals, speaker honoraria
NONE
NONE
NONE
NONE
(1) Consultant for Mentis Cura
NONE
NONE
NONE
NONE
(1) National Institute of Health Research (NIHR), United Kingdom, Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust/Newcastle University, and an NIHR Biomedical Research Centre award to Newcastle University, support for study (2012-2017). (2)National Institute of Health Research (NIHR) Programme Grant Diamond Lewy, SHAPED and PROVIDE studies, no relationship to current study.
NONE
(1) Wellcome Trust, Intermediate Clinical Fellowship (2010-2014), support to last author (Taylor) (2) Alzheimer's Research UK (2011-2014), no relationship to present study (3) Alzheimer's Society UK (2015-2018), no relationship to present study
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Neuroscience (S.J.C., I.G.M., D.J.B., J.-P.T.), Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne; SINAPSE (D.J.W.), Institute of Neuroscience and Psychology, University of Glasgow; and Department of Psychiatry (J.T.O.), University of Cambridge, UK.
- Correspondence to Dr. Colloby: sean.colloby{at}ncl.ac.uk
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Amyloid and cerebrovascular burden divergently influence brain functional network changes over timeJoanna Su Xian Chong, Hyemin Jang, Hee Jin Kim et al.Neurology, September 11, 2019 -
Research Article
Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 MonthsElie Matar, Simon R. White, John-Paul Taylor et al.Neurology, August 17, 2021 -
Articles
Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodiesMarco Onofrj, Laura Bonanni, Lamberto Manzoli et al.Neurology, May 17, 2010 -
Articles
Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer diseaseJ.E. Galvin, J.L. Price, Z. Yan et al.Neurology, April 27, 2011